The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener's granulomatosis

Clinical and Experimental Rheumatology

Volumn 26, Issue 3 SUPPL. 49, 2008, Pages

  Assmann, Gunter ^a   Wieczorek, Stefan ^b   Wibisono, Dennis ^c   Roemer, Klaus ^a   Arning, Larissa ^b   Voswinkel, Jan ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

MDM2; P53; Polymorphism; Wegener's granulomatosis

Indexed keywords

CYTOSINE; GUANINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN MDM2; PROTEIN P53; THYMINE;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; ONSET AGE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; WEGENER GRANULOMATOSIS;

EID: 52049095762     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. SCHOENERMARCK U, LAMPRECHT P, CSERNOK E, GROSS WL: Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology 2001; 40: 178-84.
2. MAHR A, GUILLEVIN L, POISSONNET M, AYMÉ S: Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: A capture-recapture estimate. Arthritis Care Res 2004; 51: 92-9.
3. WATTS RA, LANE SE, BENTHAM G, SCOTT DGI: Epidemiology of systemic vasculitis: A ten-year study in the United Kingdom. Arthritis Rheum 2000; 43: 414-9.
4. MAHR AD, NEOGI T, MERKEL PA: Epidemiology of Wegener's granulomatosis: lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin Exp Rheumatol 2006; 24 (Suppl. 41): 82-91.
5. SPRIEWALD BM, WITZKE O, WASSMUTH R et al.: Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis. Ann Rheum Dis 2005; 64: 457-61.
6. MURAKÖZY G, GAEDE KI, RUPRECHT B et al.: Gene polymorphisms of immunoregulatory cytokines and angiotensin-converting enzyme in Wegener's granulomatosis. J Mol Med 2001; 79: 665-70.
7. ZHOU Y, GISCOMBE R, HUANG D, LEFVERT AK: Novel genetic association of Wegener's granulomatosis with the interleukin 10 gene. J Rheumatol 2002; 29: 317-20.
8. BORGMANN S, HAUBITZ M: Genetic impact of pathogenesis and prognosis of ANCA-associated vasculitides. Clin Exp Rheumatol 2004; 22: 79-86.
9. GISCOMBE R, WANG X, HUANG D, LEFVERT AK: Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener's granulomatosis. J Rheumatol 2002; 29: 950-3.
10. JAGIELLO P, GENCIK M, ARNING L et al.: New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet 2004; 114: 468-77.
11. HECKMANN M, HOLLE JU, ARNING L et al.: The Wegener's Granulomatosis quantitative trait locus on chromosome 6p21.3 as characterized by tagSNP genotyping. Ann Rheum Dis 2008; 67: 972-9.
12. KUHN HM, KROMMINGA A, FLAMMANN HT, FREY M, LAYER P, ARNDT R: P53 autoantibodies in patients with autoimmune diseases: A quantitative approach. Autoimmunity 1999: 31: 229-35.
13. VOGELSTEIN B, LANEE D, LEVINE AJ: Surfing the p53 network. Nature 2000; 408: 307-10.
14. BOND GL, HU W, BOND EE et al.: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
15. BOLTZE C, ROESSNER A, LANDT O et al.: Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol 2002; 21: 1151-7.
16. GUDKOV AV, KOMAROVA EA: DangerouT habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 2007; 16: 67-72.
17. KOMAROVA EA, KRIVOKRYSENKO V, WANG K et al.: P53 is a suppressor of inflammatory response in mice. FASEB J 2005; 19: 1030-2.
18. FIRESTEIN GS, MANNING AM: Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999; 42: 609-21.
19. LEAVITT RY, FAUCI AS, BLOCH DA et al.: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
20. YOO J, AEO B, KIM Y: SNPAnalyzer: a web-based integrated workbench for single-nucleotide polymorphism analysis. Nucleic Acids Res 2005; 33: 483-8.
21. HAN Z, BOYLE DL, SHI Y, GREEN DR, FIRESTEIN GS: Dominant-negative p53 mutations in rheumatoid arthritis. Arthritis Rheum 1999; 42: 1088-92.
22. YAMANISHI Y, BOYLE DL, PINKOSKI MJ et al.: Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol 2002; 160: 123-30.
23. TARANTO E, XUE JR, LACEY D et al.: Detection of the p53 regulator murine double-minute protein 2 in rheumatoid arthritis. J Rheumatol 2005; 32: 424-9.
24. MACCHIONI P, NICOLI D, CASALI B et al.: The codon 72 polymorphic variants of p53 in Italian rheumatoid arthritis patients. Clin Exp Rheumatol 2007; 25: 416-21.
25. CSERNOK E, MÜLLER A, GROSS WL: Immunopathology of ANCA-associated vasculitis. Intern Med 1999; 38: 759-65.